Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Sarcoma 5Neoplasms 5Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1MSI-H or dMMR Advanced Solid Tumors 1Lung Neoplasms 1Leiomyosarcoma 1Gynecological Cancer 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1anlotinib 1Iodine-131 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Differentiated Thyroid Cancer × anlotinib × Clear all
NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡